Veterinary Medicines

Enrotron Flavour 150 mg Tablets for dogs

Authorised
  • Enrofloxacin
Download as PDF

Product identification

Medicine name:
Enrotron Flavour 150 mg Tablets for dogs
Enrotron Flavour 150 mg tabletten voor honden
Active substance:
  • Enrofloxacin
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Enrofloxacin
    150.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01MA90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • (ID10) 100 Tablet: unspecified outer container with 1 Blister (Aluminium; PolyVinyl Chloride) with 100 Tablet
  • (ID9) 50 Tablet: unspecified outer container with 1 Blister (Aluminium; PolyVinyl Chloride) with 50 Tablet
  • (ID8) 30 Tablet: unspecified outer container with 1 Blister (Aluminium; PolyVinyl Chloride) with 30 Tablet
  • (ID7) 20 Tablet: unspecified outer container with 1 Blister (Aluminium; PolyVinyl Chloride) with 20 Tablet
  • (ID6) 10 Tablet: unspecified outer container with 1 Blister (Aluminium; PolyVinyl Chloride) with 10 Tablet
  • (ID5) 100 Tablet: unspecified outer container with 1 Blister (Aluminium; Aluminium) with 100 Tablet
  • (ID4) 50 Tablet: unspecified outer container with 1 Blister (Aluminium; Aluminium) with 50 Tablet
  • (ID3) 30 Tablet: unspecified outer container with 1 Blister (Aluminium; Aluminium) with 30 Tablet
  • (ID2) 20 Tablet: unspecified outer container with 1 Blister (Aluminium; Aluminium) with 20 Tablet
  • (ID1) 10 Tablet: unspecified outer container with 1 Blister (Aluminium; Aluminium) with 10 Tablet

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • aniMedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • aniMedica GmbH
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 106127
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0137/002
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • Finland
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Luxembourg
  • Netherlands
  • Poland
  • Slovenia
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 7/02/2022
Download

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."